Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Amends Year-End Financial Guidance to Reflect Tekmira Payout

Premium

Alnylam Pharmaceuticals this week updated its financial guidance to include the impact of its payout to Tekmira Pharmaceuticals as part of the companies' litigation settlement deal.

As reported by Gene Silencing News, this week the companies announced that they had settled their longstanding legal battle. As part of the deal, Alnylam agreed to pay Tekmira $65 million now and $10 million in milestones expected for 2013.

Previously this month, Alnylam had said it expected to end 2012 with more than $280 million in cash, cash equivalents, and marketable securities (GSN 11/8/2012).

With the settlement, however, Alnylam said this week that it will take a $65 million charge in the fourth quarter, and it now expects its year-end cash position to be more than $215 million.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.